ClinicalTrials.gg
CompletedNCT01980940Updated Jun 27, 2024Results posted

The Single Dose Pharmacokinetics of Two and Proof of Efficacy of One New Etoricoxib Gel Formulation in Participants With Osteoarthritis (MK-0663-168)

A Phase 1/2 interventional study of Etoricoxib 75 mg 4% DMSO Gel and Etoricoxib 75 mg 4% PG Gel in Osteoarthritis Pain, sponsored by Organon and Co. Completed. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-06-27.

Sponsored by Organon and Co · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies in Osteoarthritis by Organon & Co. — none open to participants now, none under way, none of them phase 3. Osteoarthritis · Organon & Co..

Enrollment
11th of 12
70 · median 508
Started
2013
the only one that year
Phase 1/2
Only one
of the 15
Registered
15th of 15
by date

Among the 15 studies in Osteoarthritis by Organon & Co., this one is the 11th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2013, is the only one in phase 1/2, and was the 15th registered.

Osteoarthritis

2,975 studies on the registry are indexed under Osteoarthritis; 435 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

None of the 15 studies in Osteoarthritis by Organon & Co. is open now. The open studies under Osteoarthritis, anywhere →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Osteoarthritis by Organon & Co. as a file.
02

Study summary

Study Part 1 is designed to assess the plasma pharmacokinetics of etoricoxib (ETOR) 4% dimethyl sulfoxide (DMSO) and propylene glycol (PG) formulations, each at 2 different doses, upon single-dose topical administration on the knee of osteoarthritis participants. Study Part 2 is designed to evaluate the efficacy of topical etoricoxib vs. placebo in the treatment of osteoarthritis of the knee. The primary hypothesis is that topical etoricoxib will be more effective than placebo in the treatment of osteoarthritis of the knee over 2 weeks of treatment as assessed by time-weighted average change from baseline on the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Visual Analogue (VA) 3.0 pain subscale.

Read the detailed description

Part I of the study will consist of a single-dose, open-label, randomized, four-way cross over study with topical administration of etoricoxib gel on the knee of osteoarthritis participants. The washout between successive dose administrations will be at least one week. Part 2 of the study will consist of double-blind, randomized, placebo-controlled, parallel groups, multiple dose, twice daily topical administration of etoricoxib or placebo gel on the knee of osteoarthritis participants for a period of two weeks.

03

Conditions studied

  • Osteoarthritis Pain
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has diagnosis of osteoarthritis of the knee (tibio-femoral joint) for >6 months based on clinical and radiographic criteria;
  • Has a diagnosis of American Rheumatology Association (ARA) functional Class I, II, or III;
  • The knee designated as the "study joint" must be the participant's primary source of pain/disability in the lower extremity. If both knees are affected, the most painful joint will be selected for evaluation for inclusion and clinical response;
  • Female participants of must demonstrate a serum beta human chorionic gonadotropin (β-hCG) level consistent with a non-gravid state at the screening visit and urine β-hCG at Day -1 prior to first dosing and agree to use adequate oral or barrier or abstain from sexual contact at least 7 days prior to treatment and continuing through the treatment period or a discontinuation visit;
  • Willing to limit alcohol intake (beer 8 ounces, wine 4 ounces, liquor 1 ounce) to no more than 14 drinks a week (no more than 2 in a day) and to avoid unaccustomed strenuous physical activity (e.g., unaccustomed weight lifting, initiation of physical therapy) for the duration of the study;
  • Judged to be in general good health with the exception of osteoarthritis based on medical history, physical examination, and routine laboratory tests.
  • For Part 2, if the participant is a regular user of non-steroidal anti-inflammatory drugs (NSAIDs) including coxibs he/she must report a history of positive therapeutic benefit in osteoarthritis of the knee with NSAID/coxibs in the past;
  • For Part 2, participants must be taking a single NSAID on a regular basis and at a prescription strength for at least 30 days prior to study screening ("regular basis" is defined as at least 25 of the previous 30 days) for treatment of symptoms of osteoarthritis.

Exclusion criteria

Exclusion Criteria:

  • Has a concurrent medical/arthritic disease;
  • History of acute ligamentous or meniscal injury of the study joint within the previous 2 years or arthroscopy of the affected knee within 6 months prior to study entry;
  • Is a candidate for imminent joint replacement;
  • Has clinical or laboratory evidence of significant renal, gastrointestinal, pulmonary, hepatic, endocrine, neurological (apart from migraine), or other systemic disease that in the opinion of the investigator contraindicates the use of etoricoxib;
  • Has congestive heart failure with symptoms that occur at rest or minimal activity;
  • Has unstable angina that occurs at rest or with minimal activity;
  • Has uncontrolled hypertension (sitting diastolic blood pressure >95 mm Hg, or sitting systolic blood pressure >165 mm Hg);
  • Has a history of stroke or (TIA) within the previous 6 months;
  • Has a history of hepatitis/hepatic disease that has been active within the previous 2 years;
  • Has a history of neoplastic disease;
  • Is currently a user (including "recreational use") of any illicit drugs, or has a history of drug or alcohol abuse within the past 5 years;
  • Is allergic of has to aspirin, ibuprofen, rofecoxib, celecoxib, valdecoxib, other NSAIDs, acetaminophen, or sulfa drugs;
  • Has used intravenous, intramuscular, or oral within 1 month of study entry;
  • Has used glucosamine and/or chondroitin sulfate for \<6 months prior to study start;
  • Has used intra-articular steroids, HYALGAN™ (sodium hyaluronate, Sanofi Pharmaceuticals), or SYNVISC™ (hylan G-F 20, Wyeth-Ayerst Pharmaceuticals) to the study joint within 3 months of entry into the study or intra-articular steroids, HYALGAN™, or SYNVISC™ to any other joint within 1 month of study entry;
  • Has used topical, oral or systemic analgesic medications within 2 weeks of study entry and for the duration of the study;
  • Requires treatment with warfarin, heparin, high-dose aspirin (>325 mg), or digoxin;
  • Has used Arcoxia® within 2 weeks of study entry.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Pt 1: ETOR 75 DMSO/ETOR 150 PG/ETOR 75 PG/ETOR 150 DMSO

    Single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel. All treatments were applied topically.

    Drug: Etoricoxib 75 mg 4% DMSO Gel · Drug: Etoricoxib 75 mg 4% PG Gel · Drug: Etoricoxib 150 mg 4% DMSO Gel · Drug: Etoricoxib 150 mg 4% PG Gel

  • Experimental
    Pt 1: ETOR 75 PG/ETOR 75 DMSO/ETOR 150 DMSO/ETOR 150 PG

    Single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel. All treatments were applied topically.

    Drug: Etoricoxib 75 mg 4% DMSO Gel · Drug: Etoricoxib 75 mg 4% PG Gel · Drug: Etoricoxib 150 mg 4% DMSO Gel · Drug: Etoricoxib 150 mg 4% PG Gel

  • Experimental
    Pt 1: ETOR 150 DMSO/ETOR 75 PG/ETOR 150 PG/ETOR 75 DMSO

    Single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel. All treatments were applied topically.

    Drug: Etoricoxib 75 mg 4% DMSO Gel · Drug: Etoricoxib 75 mg 4% PG Gel · Drug: Etoricoxib 150 mg 4% DMSO Gel · Drug: Etoricoxib 150 mg 4% PG Gel

  • Experimental
    Pt 1: ETOR 150 PG/ETOR 150 DMSO/ETOR 75 PG/ETOR 75 DMSO

    Single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel. All treatments were applied topically.

    Drug: Etoricoxib 75 mg 4% DMSO Gel · Drug: Etoricoxib 75 mg 4% PG Gel · Drug: Etoricoxib 150 mg 4% DMSO Gel · Drug: Etoricoxib 150 mg 4% PG Gel

  • Experimental
    Pt 1: ETOR OD/ ETOR 150 DMSO/ ETOR 75 DMSO/ ETOR 75 PG

    Single-dose etoricoxib 163 mg (4.30 mL) 4% DMSO gel (DMSO formulation administered in error/overdose \[OD\]), followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel. All treatments were applied topically.

    Drug: Etoricoxib 75 mg 4% DMSO Gel · Drug: Etoricoxib 75 mg 4% PG Gel · Drug: Etoricoxib 150 mg 4% DMSO Gel · Drug: Etoricoxib 163 mg 4% DMSO gel

  • Other
    Pt 1: Placebo (Deviation)

    Participants randomized to a treatment sequence in Part 1 who received single dose placebo gel (1.97 or 3.94 mL) applied topically in error instead of active study drug and dropped out after the first treatment period in the sequence. Included in the safety assessments only.

    Drug: Placebo

  • Experimental
    Pt 2: ETOR 50 DMSO

    Etoricoxib 50 mg (1.31 mL, 4% DMSO gel) applied topically twice daily to the affected knee for a period of 2 weeks.

    Drug: Etoricoxib 50 mg 4% DMSO

  • Placebo comparator
    Pt 2: Placebo

    Matching placebo to etoricoxib 50 mg 1.31 mL 4% DMSO gel applied topically twice daily to the affected knee for a period of 2 weeks.

    Drug: Matching Placebo to Etoricoxib 50 mg 4% DMSO Gel

Interventions

06

What researchers measure

Primary outcomes

  1. Study Part 1: Maximum Concentration (Cmax) of ETOR After Single Dosing

    Cmax determined for the period up to 72 hours post-single application. Descriptive statistics are expressed as the geometric least squares mean (GLSM). Cmax with value 0 included in calculation of GLSMs with a value of 0.5\*LLOQ (=0.5 h\*ng/ml).

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, 24, 36, 48, and 72 hours post-application

  2. Study Part 1: Time to Maximum Concentration (Tmax) of ETOR After Single Dosing

    Tmax determined for the period up to 72 hours post-single application.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, 24, 36, 48, and 72 hours post-application

  3. Study Part 1: Area Under the Concentration-time Curve of ETOR From Time 0 to Last (AUC0-last) After Single Dosing

    Area under the observed concentration-time curve from time zero to the last quantifiable time point determined for the period up to 72 hours post-single application. The area was calculated according to the linear up/log down trapezoidal rule. AUC0-last is an estimate of total plasma exposure. Descriptive statistics are expressed as the GLSM. AUC with value 0 included in calculation of GLSMs with a value of 0.5\*LLOQ (=0.5 h\*ng/ml).

    Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, 24, 36, 48, and 72 hours post-application

  4. Study Part 2: Change From Baseline in Mean Participant Score on the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Visual Analog (VA) 3.1 Pain Scale

    The WOMAC VA 3.1 Pain subscale is a self-administered questionnaire assessing lower extremity pain due to osteoarthritis that was completed by participants 2 to 3 hours post morning dose. The WOMAC Pain Subscale had five questions with answers to each item assessed on a 100 mm VA scale (0 = no pain; 100 = extreme pain). The score for each item was summed and the overall score ranged from 0 to 500 (increasing severity). The time weighted average up to day x was calculated as the sum of rectangles under the curve for successive intervals prior to day x as defined by timepoints at which assessments were made. The time weighted change from baseline was calculated. A negative mean change from baseline indicates improvement in pain.

    Time frame: Baseline (Day -1), Day 2, Day 4, Day 7, Day 11, Day 14

Secondary outcomes

  1. Study Part 2: Change From Baseline in Mean Participant Score on the WOMAC VA 3.1 Stiffness Scale

    The WOMAC VA 3.1 Stiffness subscale is a self-administered questionnaire assessing lower extremity stiffness due to osteoarthritis that was completed by participants 2 to 3 hours post morning dose. The WOMAC Stiffness subscale had two questions with answers to each item assessed on a 100 mm VA scale (0 = no stiffness; 100 = extreme stiffness). The score for each item was summed and the overall score ranged from 0 to 200 (increasing severity). The time weighted average up to day x was calculated as the sum of rectangles under the curve for successive intervals prior to day x as defined by timepoints at which assessments were made. The time weighted change from baseline was calculated. A negative mean change from baseline indicates improvement in stiffness.

    Time frame: Baseline (Day -1), Day 2, Day 4, Day 7, Day 11, Day 14

  2. Study Part 2: Change From Baseline in Mean Participant Score on the WOMAC VA 3.1 Physical Functioning Scale

    The WOMAC VA 3.1 Physical Functioning subscale is a self-administered questionnaire assessing lower extremity physical function due to osteoarthritis that was completed by participants 2 to 3 hours post morning dose. The WOMAC Physical Functioning subscale had 17 questions with answers to each item assessed on a 100 mm VA scale (0 = no difficulty; 100 = extreme difficulty). The score for each item was summed and the overall score ranged from 0 to 1700 (increasing severity). The time weighted average up to day x was calculated as the sum of rectangles under the curve for successive intervals prior to day x as defined by timepoints at which assessments were made. The time weighted change from baseline was calculated. A negative mean change from baseline indicates improvement in physical function.

    Time frame: Baseline (Day -1), Day 2, Day 4, Day 7, Day 11, Day 14

  3. Study Part 2: Percentage of Participants by Category on Patient Global Assessment of Response to Therapy (PGART)

    The PGART is a self-administered questionnaire completed by participants. Participant assessment of response of arthritis to study medication was assessed on a 5-point Likert scale ('very well', 'well', 'fair', 'poor', and 'very poor').

    Time frame: Day 2, Day 4, Day 7, Day 11, Day 14, post-trial (up to Day 28)

  4. Study Parts 1 and 2: Number of Participants Who Experienced at Least One Adverse Event

    An adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.

    Time frame: Study Part 1: up to Day 47; Study Part 2: up to Day 28

  5. Study Parts 1 and 2: Number of Participants Who Discontinued Study Drug Due to an Adverse Event

    An adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.

    Time frame: Study Part 1: up to Day 47; Study Part 2: up to Day 28

07

Results

Posted Dec 11, 2015

Participant flow

Participant flow — Overall Study
MilestonePt 1: ETOR 75 DMSO/ETOR 150 PG/ETOR 75 PG/ETOR 150 DMSOPt 1: ETOR 75 PG/ETOR 75 DMSO/ETOR 150 DMSO/ETOR 150 PGPt 1: ETOR 150 DMSO/ETOR 75 PG/ETOR 150 PG/ETOR 75 DMSOPt 1: ETOR 150 PG/ETOR 150 DMSO/ETOR 75 PG/ETOR 75 DMSOPt 1: ETOR OD/ ETOR 150 DMSO/ ETOR 75 DMSO/ ETOR 75 PGPt 1: Placebo (Deviation)Pt 2: ETOR 50 DMSOPt 2: Placebo
Started5553222424
Treated5553222424
Completed5553202424
Not completed00000200
Withdrew: Protocol violation00000200

Outcome measures

PrimaryStudy Part 1: Maximum Concentration (Cmax) of ETOR After Single Dosing

Cmax determined for the period up to 72 hours post-single application. Descriptive statistics are expressed as the geometric least squares mean (GLSM). Cmax with value 0 included in calculation of GLSMs with a value of 0.5\*LLOQ (=0.5 h\*ng/ml).

Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, 24, 36, 48, and 72 hours post-application
Reported as:
Least squares mean · mg
Study Part 1: Maximum Concentration (Cmax) of ETOR After Single Dosing
mgETOR 75 DMSOETOR 75 PGETOR 150 DMSOETOR 150 PGETOR ODPlacebo (Pt 1) (Deviation)
Study Part 1: Maximum Concentration (Cmax) of ETOR After Single Dosing12.39 ± 8.242.43 ± 2.1427.30 ± 15.303.74 ± 3.79——
Statistical analysis
  • ETOR 75 DMSO vs ETOR 75 PG · ANOVA · Treatment ratio: 5.09 · 90% CI 4.03 to 6.42
  • ETOR 150 DMSO vs ETOR 150 PG · ANOVA · Treatment ratio: 7.30 · 90% CI 6.05 to 8.81
  • ETOR 75 DMSO vs ETOR 150 DMSO · ANOVA · Treatment ratio: 0.45 · 90% CI 0.38 to 0.55
  • ETOR 75 PG vs ETOR 150 PG · ANOVA · Treatment ratio: 0.65 · 90% CI 0.51 to 0.83
PrimaryStudy Part 1: Time to Maximum Concentration (Tmax) of ETOR After Single Dosing

Tmax determined for the period up to 72 hours post-single application.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, 24, 36, 48, and 72 hours post-application
Reported as:
Median · hour
Study Part 1: Time to Maximum Concentration (Tmax) of ETOR After Single Dosing
hourETOR 75 DMSOETOR 75 PGETOR 150 DMSOETOR 150 PGETOR ODPlacebo (Pt 1) (Deviation)
Study Part 1: Time to Maximum Concentration (Tmax) of ETOR After Single Dosing30.0 (23.5 to 72.0)48.0 (1.0 to 72.0)24.0 (2.0 to 72.0)48 (24.0 to 72.0)36.0 (24.0 to 48.0)—
PrimaryStudy Part 1: Area Under the Concentration-time Curve of ETOR From Time 0 to Last (AUC0-last) After Single Dosing

Area under the observed concentration-time curve from time zero to the last quantifiable time point determined for the period up to 72 hours post-single application. The area was calculated according to the linear up/log down trapezoidal rule. AUC0-last is an estimate of total plasma exposure. Descriptive statistics are expressed as the GLSM. AUC with value 0 included in calculation of GLSMs with a value of 0.5\*LLOQ (=0.5 h\*ng/ml).

Time frame:
Predose and 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, 24, 36, 48, and 72 hours post-application
Reported as:
Least squares mean · mg
Study Part 1: Area Under the Concentration-time Curve of ETOR From Time 0 to Last (AUC0-last) After Single Dosing
mgETOR 75 DMSOETOR 75 PGETOR 150 DMSOETOR 150 PGETOR ODPlacebo (Pt 1) (Deviation)
Study Part 1: Area Under the Concentration-time Curve of ETOR From Time 0 to Last (AUC0-last) After Single Dosing611.3 ± 400.9765.6 ± 112.831309.7 ± 686.34161.3 ± 172.96——
Statistical analysis
  • ETOR 75 DMSO vs ETOR 75 PG · ANOVA · Treatment ratio: 9.32 · 90% CI 4.77 to 18.18
  • ETOR 150 DMSO vs ETOR 150 PG · ANOVA · Treatment ratio: 8.12 · 90% CI 6.39 to 10.32
  • ETOR 75 DMSO vs ETOR 150 DMSO · ANOVA · Treatment ratio: 0.47 · 90% CI 0.39 to 0.57
  • ETOR 75 PG vs ETOR 150 PG · ANOVA · Treatment ratio: 0.41 · 90% CI 0.21 to 0.79
PrimaryStudy Part 2: Change From Baseline in Mean Participant Score on the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Visual Analog (VA) 3.1 Pain Scale

The WOMAC VA 3.1 Pain subscale is a self-administered questionnaire assessing lower extremity pain due to osteoarthritis that was completed by participants 2 to 3 hours post morning dose. The WOMAC Pain Subscale had five questions with answers to each item assessed on a 100 mm VA scale (0 = no pain; 100 = extreme pain). The score for each item was summed and the overall score ranged from 0 to 500 (increasing severity). The time weighted average up to day x was calculated as the sum of rectangles under the curve for successive intervals prior to day x as defined by timepoints at which assessments were made. The time weighted change from baseline was calculated. A negative mean change from baseline indicates improvement in pain.

Time frame:
Baseline (Day -1), Day 2, Day 4, Day 7, Day 11, Day 14
Reported as:
Mean · Units on a scale
Study Part 2: Change From Baseline in Mean Participant Score on the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Visual Analog (VA) 3.1 Pain Scale
Units on a scaleETOR 50 DMSOPlacebo (Pt 2)
BL to Day 2-24.21 ± 76.88-37.21 ± 101.77
BL to Day 4-34.29 ± 69.15-43.92 ± 94.81
BL to Day 7-45.81 ± 67.92-54.11 ± 94.11
BL to Day 11-59.42 ± 71.12-63.60 ± 90.99
BL to Day 14-69.60 ± 75.81-72.60 ± 91.35
Statistical analysis
  • ETOR 50 DMSO vs Placebo (Pt 2) · constrained longitudinal data analysis · p = 0.2113 · Mean difference (final values): -27.3 · 90% CI -63.6 to 8.9
  • ETOR 50 DMSO vs Placebo (Pt 2) · constrained longitudinal data analysis · p = 0.2548 · Mean difference (final values): -22.7 · 90% CI -55.7 to 10.3
  • ETOR 50 DMSO vs Placebo (Pt 2) · constrained longitudinal data analysis · p = 0.2880 · Mean difference (final values): -21.4 · 90% CI -54.9 to 12.0
  • ETOR 50 DMSO vs Placebo (Pt 2) · constrained longitudinal data analysis · p = 0.3709 · Median difference (final values): -17.6 · 90% CI -50.4 to 15.1
  • ETOR 50 DMSO vs Placebo (Pt 2) · constrained longitudinal data analysis · p = 0.3883 · Mean difference (final values): -17.3 · 90% CI -50.5 to 16.0
SecondaryStudy Part 2: Change From Baseline in Mean Participant Score on the WOMAC VA 3.1 Stiffness Scale

The WOMAC VA 3.1 Stiffness subscale is a self-administered questionnaire assessing lower extremity stiffness due to osteoarthritis that was completed by participants 2 to 3 hours post morning dose. The WOMAC Stiffness subscale had two questions with answers to each item assessed on a 100 mm VA scale (0 = no stiffness; 100 = extreme stiffness). The score for each item was summed and the overall score ranged from 0 to 200 (increasing severity). The time weighted average up to day x was calculated as the sum of rectangles under the curve for successive intervals prior to day x as defined by timepoints at which assessments were made. The time weighted change from baseline was calculated. A negative mean change from baseline indicates improvement in stiffness.

Time frame:
Baseline (Day -1), Day 2, Day 4, Day 7, Day 11, Day 14
Reported as:
Mean · Units on a scale
Study Part 2: Change From Baseline in Mean Participant Score on the WOMAC VA 3.1 Stiffness Scale
Units on a scaleETOR 50 DMSOPlacebo (Pt 2)
BL to Day 2-9.17 ± 37.44-16.79 ± 41.86
BL to Day 4-14.69 ± 35.23-18.79 ± 39.29
BL to Day 7-19.34 ± 35.75-23.08 ± 37.53
BL to Day 11-24.44 ± 34.60-26.87 ± 35.26
BL to Day 14-29.22 ± 36.64-30.52 ± 34.33
Statistical analysis
  • ETOR 50 DMSO vs Placebo (Pt 2) · constrained longitudinal data analysis · p = 0.1383 · Mean difference (final values): -14.1 · 90% CI -29.7 to 1.6
  • ETOR 50 DMSO vs Placebo (Pt 2) · constrained longitudinal data analysis · p = 0.2380 · Mean difference (final values): -10.4 · 90% CI -24.9 to 4.2
  • ETOR 50 DMSO vs Placebo (Pt 2) · constrained longitudinal data analysis · p = 0.2691 · Mean difference (final values): -9.5 · 90% CI -23.9 to 4.8
  • ETOR 50 DMSO vs Placebo (Pt 2) · constrained longitudinal data analysis · p = 0.3246 · Mean difference (final values): -8.1 · 90% CI -21.8 to 5.6
  • ETOR 50 DMSO vs Placebo (Pt 2) · constrained longitudinal data analysis · p = 0.3881 · Mean difference (final values): -7.1 · 90% CI -20.9 to 6.6
SecondaryStudy Part 2: Change From Baseline in Mean Participant Score on the WOMAC VA 3.1 Physical Functioning Scale

The WOMAC VA 3.1 Physical Functioning subscale is a self-administered questionnaire assessing lower extremity physical function due to osteoarthritis that was completed by participants 2 to 3 hours post morning dose. The WOMAC Physical Functioning subscale had 17 questions with answers to each item assessed on a 100 mm VA scale (0 = no difficulty; 100 = extreme difficulty). The score for each item was summed and the overall score ranged from 0 to 1700 (increasing severity). The time weighted average up to day x was calculated as the sum of rectangles under the curve for successive intervals prior to day x as defined by timepoints at which assessments were made. The time weighted change from baseline was calculated. A negative mean change from baseline indicates improvement in physical function.

Time frame:
Baseline (Day -1), Day 2, Day 4, Day 7, Day 11, Day 14
Reported as:
Mean · Units on a scale
Study Part 2: Change From Baseline in Mean Participant Score on the WOMAC VA 3.1 Physical Functioning Scale
Units on a scaleETOR 50 DMSOPlacebo (Pt 2)
BL to Day 2-117.13 ± 200.38-153.54 ± 278.66
BL to Day 4-147.71 ± 183.07-171.35 ± 272.51
BL to Day 7-172.94 ± 186.22-199.88 ± 265.29
BL to Day 11-214.87 ± 203.95-245.05 ± 238.05
BL to Day 14-250.82 ± 218.72-280.29 ± 233.39
Statistical analysis
  • ETOR 50 DMSO vs Placebo (Pt 2) · constrained longitudinal data analysis · p = 0.4477 · Mean difference (final values): -52.3 · 90% CI -166.8 to 62.3
  • ETOR 50 DMSO vs Placebo (Pt 2) · constrained longitudinal data analysis · p = 0.6084 · Mean difference (final values): -33.7 · 90% CI -143.6 to 76.1
  • ETOR 50 DMSO vs Placebo (Pt 2) · constrained longitudinal data analysis · p = 0.5926 · Mean difference (final values): -35.2 · 90% CI -144.7 to 74.4
  • ETOR 50 DMSO vs Placebo (Pt 2) · constrained longitudinal data analysis · p = 0.5022 · Mean difference (final values): -42.3 · 90% CI -147.2 to 62.6
  • ETOR 50 DMSO vs Placebo (Pt 2) · constrained longitudinal data analysis · p = 0.5125 · Mean difference (final values): -42.0 · 90% CI -149.0 to 64.9
SecondaryStudy Part 2: Percentage of Participants by Category on Patient Global Assessment of Response to Therapy (PGART)

The PGART is a self-administered questionnaire completed by participants. Participant assessment of response of arthritis to study medication was assessed on a 5-point Likert scale ('very well', 'well', 'fair', 'poor', and 'very poor').

Time frame:
Day 2, Day 4, Day 7, Day 11, Day 14, post-trial (up to Day 28)
Reported as:
Number · Percentage of participants
Study Part 2: Percentage of Participants by Category on Patient Global Assessment of Response to Therapy (PGART)
Percentage of participantsETOR 50 DMSOPlacebo (Pt 2)
Day 2: Very well0.00.0
Day 2: Well20.833.3
Day 2: Fair25.025.0
Day 2: Poor37.533.3
Day 2: Very poor16.78.3
Day 4: Very well0.00.0
Day 4: Well20.833.3
Day 4: Fair45.837.5
Day 4: Poor29.225.0
Day 4: Very poor4.24.2
Day 7: Very well0.00.0
Day 7: Well25.037.5
Day 7: Fair50.037.5
Day 7: Poor25.025.0
Day 7: Very poor0.00.0
Day 11: Very well0.00.0
Day 11: Well37.550.0
Day 11: Fair45.837.5
Day 11: Poor16.712.5
Day 11: Very poor0.00.0
Day 14: Very well0.08.3
Day 14: Well54.250.0
Day 14: Fair41.733.3
Day 14: Poor4.28.3
Day 14: Very poor0.00.0
Post-trial: Very well8.38.3
Post-trial: Well62.550.0
Post-trial: Fair29.229.2
Post-trial: Poor012.5
Post-trial: Very poor0.00.0
Statistical analysis
  • ETOR 50 DMSO vs Placebo (Pt 2) · Jonckheere-Terpstra test · p = 0.2632
  • ETOR 50 DMSO vs Placebo (Pt 2) · Jonckheere-Terpstra test · p = 0.4703
  • ETOR 50 DMSO vs Placebo (Pt 2) · Jonckheere-Terpstra test · p = 0.5507
  • ETOR 50 DMSO vs Placebo (Pt 2) · Jonckheere-Terpstra test · p = 0.3992
  • ETOR 50 DMSO vs Placebo (Pt 2) · Jonckheere-Terpstra test · p = 0.6626
  • ETOR 50 DMSO vs Placebo (Pt 2) · Jonckheere-Terpstra test · p = 0.3150
SecondaryStudy Parts 1 and 2: Number of Participants Who Experienced at Least One Adverse Event

An adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.

Time frame:
Study Part 1: up to Day 47; Study Part 2: up to Day 28
Reported as:
Number · Participants
Study Parts 1 and 2: Number of Participants Who Experienced at Least One Adverse Event
ParticipantsETOR 75 DMSOETOR 75 PG (Pt 1)ETOR 150 DMSO (Pt 1)ETOR 150 PG (Pt 1)ETOR OD (Pt 1)Placebo (Pt 1) (Deviation)ETOR 50 DMSO (Pt 2)Placebo (Pt 2)
Study Parts 1 and 2: Number of Participants Who Experienced at Least One Adverse Event11112065
SecondaryStudy Parts 1 and 2: Number of Participants Who Discontinued Study Drug Due to an Adverse Event

An adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.

Time frame:
Study Part 1: up to Day 47; Study Part 2: up to Day 28
Reported as:
Number · Participants
Study Parts 1 and 2: Number of Participants Who Discontinued Study Drug Due to an Adverse Event
ParticipantsETOR 75 DMSOETOR 75 PG (Pt 1)ETOR 150 DMSO (Pt 1)ETOR 150 PG (Pt 1)ETOR OD (Pt 1)Placebo (Pt 1) (Deviation)ETOR 50 DMSO (Pt 2)Placebo (Pt 2)
Study Parts 1 and 2: Number of Participants Who Discontinued Study Drug Due to an Adverse Event00000000

Adverse events

Collected over Study Part 1: up to Day 47; Study Part 2: up to Day 28. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ETOR 75 DMSO (Pt 1)—0/20 (0%)0/20 (0%)
ETOR 75 PG (Pt 1)—0/20 (0%)0/20 (0%)
ETOR 150 DMSO (Pt 1)—0/20 (0%)0/20 (0%)
ETOR 150 PG (Pt 1)—0/18 (0%)1/18 (5.6%)
ETOR OD (Pt 1)—0/2 (0%)2/2 (100%)
Placebo (Pt 1) (Deviation)—0/2 (0%)0/2 (0%)
ETOR 50 DMSO (Pt 2)—0/24 (0%)2/24 (8.3%)
Placebo (Pt 2)—0/24 (0%)2/24 (8.3%)
Most frequent other events
Most frequent other events
EventETOR 75 DMSO (Pt 1)ETOR 75 PG (Pt 1)ETOR 150 DMSO (Pt 1)ETOR 150 PG (Pt 1)ETOR OD (Pt 1)Placebo (Pt 1) (Deviation)ETOR 50 DMSO (Pt 2)Placebo (Pt 2)
Accidental overdoseInjury, poisoning and procedural complications0/200/200/200/182/20/20/240/24
Urinary tract infectionInfections and infestations0/200/200/200/180/20/22/240/24
Alanine aminotransferase increasedInvestigations0/200/200/200/180/20/21/242/24
CholecystocholangitisHepatobiliary disorders0/200/200/201/180/20/20/240/24

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pt 1: ETOR 75 DMSO/ETOR 150 PG/ETOR 75 PG/ETOR 150 DMSOPt 1: ETOR 75 PG/ETOR 75 DMSO/ETOR 150 DMSO/ETOR 150 PGPt 1: ETOR 150 DMSO/ETOR 75 PG/ETOR 150 PG/ETOR 75 DMSOPt 1: ETOR 150 PG/ETOR 150 DMSO/ETOR 75 PG/ETOR 75 DMSOPt 1: ETOR OD/ ETOR 150 DMSO/ ETOR 75 DMSO/ ETOR 75 PGPt 1: Placebo (Deviation)Pt 2: ETOR 50 DMSOPt 2: PlaceboTotal
Mean61.0 ± 6.661.0 ± 12.363.6 ± 10.662.0 ± 10.055.0 ± 8.560.5 ± 4.961.5 ± 8.261.2 ± 6.761.3 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)Pt 1: ETOR 75 DMSO/ETOR 150 PG/ETOR 75 PG/ETOR 150 DMSOPt 1: ETOR 75 PG/ETOR 75 DMSO/ETOR 150 DMSO/ETOR 150 PGPt 1: ETOR 150 DMSO/ETOR 75 PG/ETOR 150 PG/ETOR 75 DMSOPt 1: ETOR 150 PG/ETOR 150 DMSO/ETOR 75 PG/ETOR 75 DMSOPt 1: ETOR OD/ ETOR 150 DMSO/ ETOR 75 DMSO/ ETOR 75 PGPt 1: Placebo (Deviation)Pt 2: ETOR 50 DMSOPt 2: PlaceboTotal
Female434310181548
Male1210126922
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in Nov 2014, 11 months.

Results were first posted in Dec 2015, 1 year after primary completion.

Of 25 phase 1/2 interventional studies under Osteoarthritis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2013
First posted
Nov 11, 2013
StartActual
Dec 23, 2013
Primary completionActual
Nov 26, 2014
CompletionActual
Nov 26, 2014
Results first posted
Dec 11, 2015
Last update
Jun 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01980940
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Nov 11, 2013
Start date
Dec 23, 2013
Primary completion
Nov 26, 2014
Completion
Nov 26, 2014
Results posted
Dec 11, 2015
Last update
Jun 27, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etoricoxib

Start the discussion